SCHEMBL1196444

SCHEMBL1196444

[CH2]CCN1CCC(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.56
PRMT6 Q96LA8 1/20 0.56
PRMT1 Q99873 1/20 0.56
PRMT8 Q9NR22 1/20 0.56
HRH3 Q9Y5N1 6/20 0.47
ACHE P22303 2/20 0.47
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
SIGMAR1 Q99720 5/20 0.43
KDM4E B2RXH2 2/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KCNA3 P22001 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2099496 0.86
SCHEMBL735708 0.86
SCHEMBL2099639 0.86
SCHEMBL6185142 0.84 CARM1 (0.43) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL20234635 0.84 CARM1 (0.65) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL6183476 0.82 CARM1 (0.40) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL23828682 0.79 CARM1 (0.60) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL538465 0.79
SCHEMBL1290932 0.77 CARM1 (0.58) CARM1PRMT6PRMT1PRMT8HRH3
SCHEMBL4373255 0.77 CARM1 (0.58) CARM1PRMT6PRMT1PRMT8HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118146262-A Bi-phosphatidyl amide compound containing multiple tertiary amino structures, composition and application thereof 北京大学 2024-06-07 CN claimed
CN-111393363-B 4-phenoxy quinoline and N-sulfonyl amidine compound and preparation method and application thereof 威海海洋生物医药产业技术研究院有限公司 2022-12-20 CN claimed
EP-3862354-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2021-08-11 EP claimed
EP-2824105-B1 Indolopyridines as Eg5 kinesin modulators 4SC AG (DE) 2021-03-31 EP claimed
CN-111393363-A 4-phenoxy quinoline and N-sulfonyl amidine compound and preparation method and application thereof 哈尔滨工业大学(威海) 2020-07-10 CN claimed
EP-2824105-A1 Indolopyridines as Eg5 kinesin modulators 4SC AG (DE) 2015-01-14 EP claimed
US-8530493-B2 Indolopyridines as Eg5 kinesin modulators 4SC AG (DE) 2013-09-10 US claimed
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP claimed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
US-20110027226-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) 4SC AG (DE) 2011-02-03 US claimed
US-20090233902-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS 4SC AG (DE) 2009-09-17 US claimed
CN-101389628-A Indolopyridines as EG5 kinesin modulators 4SC AG (DE) 2009-03-18 CN claimed
CN-101389629-A Indolopyridines as EG5 kinesin modulators 4SC AG (DE) 2009-03-18 CN claimed
EP-2033962-A1 Tetracyclic indolopyridines as EG5 inhibitors 4SC AG (DE) 2009-03-11 EP claimed
EP-1673349-A4 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S BIO PTE LTD (SG) 2008-01-23 EP claimed
JP-2007505942-A 2007-03-15 JP claimed
US-20070043043-A1 Benzimidazole derivates: preparation and pharmaceutical applications S*BIO PTE LTD. (SG) 2007-02-22 US claimed
CN-1860103-A Benzimidazole derivatives, preparation method and medical application thereof S BIO PTE LTD (SG) 2006-11-08 CN claimed
EP-1673349-A1 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*Bio Pte Ltd (SG) 2006-06-28 EP claimed
WO-2005028447-A1 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-03-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 CARM1 656/4885PRMT6 591/4885PRMT1 583/4885
US-20110027226-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) KIF5A, KIF5C, KIF5B CARM1 4523/4885PRMT6 2975/4885PRMT1 3191/4885
US-20070043043-A1 Benzimidazole derivates: preparation and pharmaceutical applications HDAC5, HDAC1, HDAC4 CARM1 212/4885PRMT6 1597/4885PRMT1 1075/4885
US-20090233902-A1 INDOLOPYRIDINES AS EG5 KINESIN MODULATORS KIF5A, KIF5C, KIF5B CARM1 3954/4885PRMT6 2300/4885PRMT1 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.